U.S. market Open. Closes in 1 hour 40 minutes

SYRE | Spyre Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue886.00K2.33M18.74MN/AN/A3.89M5.21M4.63M
Cost of Revenue964.00K1.96M2.00M1.62M901.00KN/AN/AN/A
Gross Profit-78.00K365.00K16.74M-1.62M-901.00K3.89M5.21M4.63M
Operating Expenses243.19M87.11M84.39M81.48M79.43M49.06M32.63M26.40M
Selling, General & Admin39.95M28.53M27.32M21.84M14.83M12.34M9.82M8.26M
Research & Development89.50M58.58M57.07M59.64M64.60M36.72M22.82M18.14M
Other Operating Expenses113.74M-7.00K-122.00K-5.00KN/AN/AN/AN/A
Operating Income-242.30M-84.78M-65.65M-81.48M-80.33M-45.46M-27.68M-21.91M
Other Expenses / Income-96.51M830.00K-11.00K588.00K2.08M1.11M440.00K208.00K
Before Tax Income-338.82M-83.95M-65.66M-80.89M-78.25M-44.35M-27.24M-21.70M
Income Tax Expenses-26.00K-136.00K141.00K-593.00KN/AN/AN/AN/A
Net Income-338.79M-83.81M-65.80M-80.89M-78.25M-44.35M-27.24M-21.70M
Interest ExpensesN/AN/AN/AN/AN/AN/AN/AN/A
Basic Shares Outstanding6.90M3.37M2.63M2.13M1.28M832.90K605.13K391.67K
Diluted Shares Outstanding6.90M3.37M2.63M2.13M1.28M832.90K605.13K391.67K
EBITDA-127.82M-83.21M-63.66M-79.27M-77.35M-45.17M-27.43M-21.77M
EBITDA Margin-14,426.64%-3,572.95%-339.71%0.00%0.00%-1,161.78%-526.94%-470.48%
EBIT-338.82M-83.95M-65.66M-81.49M-78.25M-44.35M-27.24M-21.70M
EBIT Margin-38,241.08%-3,604.59%-350.39%0.00%0.00%-1,140.64%-523.27%-468.84%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙